Ella Emergency Contraceptive Approved

Intended to inhibit or delay ovulation
By Scott Roberts
HealthDay Reporter

MONDAY, Aug. 16 (HealthDay News) -- The ella (ulipristal acetate) emergency contraceptive has been approved by the U.S. Food and Drug Administration. It's been available in Europe for more than a year under the brand name ellaOne.

To be taken within five days of contraceptive failure or unprotected intercourse, the drug is not meant to be used as a routine contraceptive, according to the FDA. Ella's safety and effectiveness were demonstrated in studies conducted in the United States, United Kingdom, and Ireland. The most common side effects included headache, nausea, abdominal pain, menstrual pain, fatigue, and dizziness.

Women with known or suspected pregnancy or those who are breast-feeding shouldn't use ella, according to the FDA.

The drug is distributed by Watson Pharma Inc., based in Morristown, N.J.

More information

The FDA has more about this approval.

Copyright © 2010 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events